Drug Enforcement Administration
Skip Navigation

Press Room
News Releases
E-mail updates red envelope
Speeches & Testimony
Multi-Media Library

About Us
Mission
Leadership
History
Organizational Chart
Programs & Operations
Wall of Honor
DEA Museum
Office Locations

Careers at DEA

Drug Information

Law Enforcement
Most Wanted
Major Operations
Threat Assessment
Training Programs
Stats & Facts
Additional Resources

Drug Prevention
For Young Adults
Additional Resources

Diversion Control & Prescription Drugs
Registration
Cases Against Doctors

Drug Policy
Controlled Substances Act
Federal Trafficking Penalties
Drug Scheduling

Legislative Resources

Publications

Acquisitions & Contracts

News Release [print friendly page]
FOR IMMEDIATE RELEASE
April 4, 2007
Contact: SA Sarah Pullen
Public Information Officer
Number: 213-621-6827

DEA Seizes Operational GHB Lab in Newport Beach, California

APR 4 -- (Los Angeles, California) – Ralph W. Partridge, Acting Special Agent in Charge of the Drug Enforcement Administration (DEA) Los Angeles Field Division announced the seizure of an operational GHB laboratory at an apartment in Newport Beach, California. Earlier today in a joint investigation, DEA Agents and officers from the Westminster Police Department served a search warrant and found the GHB lab. In addition to the GHB lab, agents seized approximately 3 gallons of GHB, as well as quantities of methamphetamine, cocaine, MDMA (ecstasy) and ketamine, as well as chemicals involved in the manufacture of GHB. The GHB lab was capable of producing up to 2 kilograms of solid GHB at a time. Two individuals have been arrested.

GHB, gamma-hydroxybutyrate, is a powerful central nervous system depressant that the human body produces in small amounts. A synthetic version of GHB was developed in the 1920s as an anesthetic. Individuals abuse synthetic GHB because of its euphoric and sedative effects. Due to its anesthetic properties, GHB also has been used by sexual predators to incapacitate their victims. GHB and its analogs are illegal and are listed as Schedule I substances under the Controlled Substances Act. Schedule I drugs have a high potential for abuse and serve no legitimate medical purpose.

This is an on-going DEA investigation and leads are being actively pursued and developed. Further information will be disseminated to press outlets when available for release. Please forward any questions to DEA Los Angeles Public Information Officer SA Sarah Pullen at (213) 621-6827.

 

Home USDOJ.GOV Privacy Policy Contact Us Site Map